Drug news
KRX-0401 (Keryx/Aeterna Zentaris) fails X-PECT trial for Colorectal Cancer
Aeterna Zentaris Inc. has announced that the Phase III "X-PECT" (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine + capecitabine (Xeloda) in patients with refractory advanced Colorectal Cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo. The trial involving 468 patients in 65 sites in the U.S was conducted by Keryx Biopharmaceuticals, Inc. which holds the US rights as licensee.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.